<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-75841" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Crotalidae Envenomation</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Buchanan</surname>
            <given-names>James T.</given-names>
          </name>
          <aff>Norton Health, University of Louisville</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thurman</surname>
            <given-names>Jeff</given-names>
          </name>
          <aff>University of Louisville/Norton Healthcare</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>James Buchanan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeff Thurman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>3</day>
          <month>10</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-75841.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Crotalid envenomations cause a spectrum of disease, with both localized and systemic toxicity, which can result in both prolonged morbidity and rarely mortality. This activity reviews the evaluation and management of patients who suffer from crotalid envenomations and highlights the interprofessional team's importance in managing these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Assess&#x000a0;the common components of North American crotalid venom and how these result in clinical toxicity.</p></list-item><list-item><p>Identify the indications for crotalid antivenom and the common side effects encountered with treatment.</p></list-item><list-item><p>Evaluate&#x000a0;therapies that are and are not recommended in the treatment of crotalid envenomations.</p></list-item><list-item><p>Communicate&#x000a0;the importance of collaboration and communication among the interprofessional team to improve outcomes for patients who suffer crotalid envenomations.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=75841&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=75841">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-75841.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Crotalidae</italic>, colloquially known as pit vipers, are venomous snakes throughout the continental United States and Canada. <italic toggle="yes">Crotalidae</italic> envenomation represents an uncommon but clinically important illness that can result in significant morbidity and rarely mortality. Pitviper&#x000a0;venom contains a variety of substances that cause cytotoxicity, myotoxicity, hemotoxicity, and, less commonly, neurotoxicity.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref> These envenomations can result in a spectrum of disease severity, the extent of which is not always apparent at the initial evaluation. Careful evaluation and monitoring are needed to prevent serious sequelae.</p>
      </sec>
      <sec id="article-75841.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>In the US,&#x000a0;3 types of <italic toggle="yes">Crotalidae exist</italic>, copperhead (<italic toggle="yes">Agkistrodon contortrix</italic>), cottonmouth (<italic toggle="yes">Agkistrodon piscivorus</italic>), and multiple species of rattlesnakes (<italic toggle="yes">Crotalus</italic> and <italic toggle="yes">Sistrurus</italic> sp.), which have a wide distribution throughout the United States except for Hawaii and Alaska.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r4">[4]</xref> Definitive characteristics of these snakes include triangular heads, elliptical eyes, and heat-seeking pits between their eyes and nostrils.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> Given that particular species vary by state and region, knowledge of local geographic distribution can guide proper identification.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref></p>
      </sec>
      <sec id="article-75841.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Estimates of the number of people who suffer a snakebite each year vary between 5000&#x000a0;and 9000.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r5">[5]</xref> Males are more likely to suffer envenomations than females, with the vast majority being Caucasian.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r6">[6]</xref> The majority of victims are young adults aged between 20 and 40.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r7">[7]</xref><xref ref-type="bibr" rid="article-75841.r6">[6]</xref>&#x000a0;A smaller peak in those under 12 years of age leads to the bimodal age distribution of envenomations.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r7">[7]</xref><xref ref-type="bibr" rid="article-75841.r6">[6]</xref>&#x000a0;Envenomations typically occur in the distal extremities.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r7">[7]</xref><xref ref-type="bibr" rid="article-75841.r6">[6]</xref> Lower extremity envenomations are the most common location and usually occur with incidental contact. Upper extremity envenomations, by contrast, are more likely to be due to intentional contact.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r7">[7]</xref><xref ref-type="bibr" rid="article-75841.r6">[6]</xref> Envenomations typically occur when pit vipers are most active in late spring to early fall.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref> There is a higher incidence of bites at dawn and dusk, which are peak hunting times for pit vipers.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref> The majority of envenomations are due to rattlesnakes and copperheads, which account for 50&#x000a0;to 55% and 30&#x000a0;to 45% of cases, respectively. cottonmouth envenomations are rare, contributing to only 5&#x000a0;to 10% of cases.<xref ref-type="bibr" rid="article-75841.r4">[4]</xref><xref ref-type="bibr" rid="article-75841.r8">[8]</xref>&#x000a0;Bites involving larger snakes are associated with more severe envenomations, likely due to their more substantial venom reserves.<xref ref-type="bibr" rid="article-75841.r9">[9]</xref></p>
      </sec>
      <sec id="article-75841.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Snake venom is a mixture of&#x000a0;multiple compounds with different physiologic effects. The specific constitution of an individual snake&#x02019;s venom varies by species, geographic location, diet, and even between siblings.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Most North American crotalid venom generally contains proinflammatory, hemotoxic, cytotoxic, and myotoxic compounds.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref>&#x000a0;Venom is rapidly absorbed but slowly eliminated.<xref ref-type="bibr" rid="article-75841.r3">[3]</xref>&#x000a0;Examples of specific compounds identified and their actions:</p>
        <list list-type="bullet">
          <list-item>
            <p>Snake venom metalloproteinase has both pro- and anti-coagulation effects.&#x000a0;It also contributes to the development of edema, myotoxicity, and inflammation.<xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Snake venom serine protease targets the coagulation cascade and causes platelet aggregation.<xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Phospholipase A2 has anticoagulant, cytotoxic, and myotoxic effects. It also contributes to the development of edema.<xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Disintegrins and C-type lectins modulate platelet aggregation.<xref ref-type="bibr" rid="article-75841.r2">[2]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>Neurotoxins are uncommon among North American Crotalids. However,&#x000a0;3 particular species: Mojave rattlesnake (<italic toggle="yes">C. scutulatus</italic>), Timber rattlesnake (<italic toggle="yes">C. horridus</italic>), Southern Pacific rattlesnakes (<italic toggle="yes">C. oreganus helleri</italic>) are known to have the Mojave A or a similar presynaptic neurotoxin.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r9">[9]</xref></p>
      </sec>
      <sec id="article-75841.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The first step when evaluating potential snake envenomation victims is to assess the ABCs: airway, breathing, and circulation.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> If there is any compromise to these systems, immediate intervention is warranted before continuing with further history and exams. Head and neck envenomation is uncommon but can cause significant swelling, which may affect the airway. If envenomation to the head and neck area results in signs of airway compromise, early endotracheal intubation should occur&#x000a0;because of the high likelihood of subsequent airway loss.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref> Distal envenomations can precipitate airway compromise by inducing angioedema.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref> Severe envenomations can result in circulatory collapse from massive hemorrhage, third spacing, and hemolysis.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref> If the venom contains a neurotoxin, patients may suffer impairment of respiratory function.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref></p>
        <p>When&#x000a0;obtaining a history from&#x000a0;a victim of potential envenomation without compromised ABCs, several pieces of information are necessary. The time since the envenomation occurred and the anatomic location of the bite should be&#x000a0;asked to allow for appropriate monitoring of local symptom progression.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> While correctly identifying the species involved in the potential envenomation is important, attempting to kill or capture the snake is not advised as it can result in additional bites or victims. A picture obtained with a cellphone or other portable device is usually sufficient for identification and can be obtained from a distance safe enough to avoid further envenomation.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> Again, it should be stressed that preventing additional bites or victims is more important than correctly identifying the snake. Both the public and&#x000a0;medical professionals require education on this recommendation. Despite these recommendations, it is not unusual for victims to bring a dead snake. Healthcare providers should understand that handling dead snakes can be dangerous as post-mortem envenomations can occur.<xref ref-type="bibr" rid="article-75841.r11">[11]</xref></p>
        <p>As mentioned above, the first step in any physical exam is assessing&#x000a0;the cardiopulmonary system to identify signs of compromise. Next, examine the envenomation site, which likely reveals 2 puncture wounds a few centimeters apart. The leading edge of the erythema/edema should be marked to monitor for progression.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;Pulse, sensation, and motor function distal to the envenomation also need testing. Remove any restrictive jewelry or clothing, as swelling may progress.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>A further skin assessment should focus on signs of abnormal bleeding, such as petechiae or ecchymosis. A thorough&#x000a0;head-to-toe exam should be completed to look for other sequelae of envenomation.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref></p>
        <p>The most common localized findings following pit viper envenomation are pain, edema, ecchymosis, and erythema in descending order. Tissue necrosis is possible and more likely to occur with rattlesnake envenomation. Systemic symptoms occur in 15% of patients or less. Systemic manifestations include vomiting, bleeding from distal sites (eg, gingival bleeding or epistaxis), and signs of neurotoxicity (eg, fasciculations, myokymia, cranial nerve palsies, paresthesias, or respiratory paralysis).<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Hypotension and angioedema, though uncommon, require prompt attention and management.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;Providers should assess other symptoms such as chest pain, abdominal pain, headache, etc.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> These symptoms may be a complication of envenomation, such as hemorrhage or thrombosis, but may represent a completely separate disease process.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;While rattlesnakes are generally recognized as causing more severe envenomations than their <italic toggle="yes">Agkistrodon</italic> counterparts, species alone does NOT dictate the degree of envenomation. Management should be based on a combination of history, physical, and lab abnormalities, regardless of the species involved.</p>
      </sec>
      <sec id="article-75841.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>All potential victims of pit viper envenomation should have a complete blood count (CBC), partial thromboplastin time (PTT), prothrombin time (PT), international normalized ratio (INR), and fibrinogen level checked where available.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;When reviewing the CBC, note any thrombocytopenia or anemia. The other tests attempt to quantify any degree of coagulopathy.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;If fibrinogen is not available, a D-dimer is an optional substitute. Fibrinogen is more specific for coagulopathies, but the D-dimer is more sensitive.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Fibrin splint products have no role in the evaluation of pit viper envenomation.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref> Additional tests are used to evaluate for complications related to envenomations. A comprehensive metabolic profile can be useful to assess for hepatic or renal dysfunction.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> A urinalysis and total creatine kinase can evaluate for possible rhabdomyolysis.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Any further testing should be ordered based on patient complaints, eg, a patient presenting with chest pain after an envenomation should have an EKG and troponin ordered.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-75841.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>As with other soft tissue injuries, all patients with a pit viper envenomation should have their Tetanus updated and receive local wound care with soap/water.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Patients should also receive adequate pain control. Despite their efficacy in controlling pain and inflammation, clinicians should avoid NSAIDs due to the potential to worsen coagulopathy and platelet aggregation.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;Because of this theoretical risk, opioid analgesics are the recommended agents for adequate pain control.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref> Consultation with the regional poison control center can be extremely valuable in assisting with the nuances of a particular case.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;Each center can provide access to an on-call toxicologist if sub-specialist level advice is warranted. Further treatment recommendations are based on the severity of envenomation, which broadly falls into&#x000a0;4 categories.</p>
        <list list-type="bullet">
          <list-item>
            <p>Dry: Approximately 20&#x000a0;to 25% of bites result in no&#x000a0;envenomation. These patients are largely asymptomatic and have minimal localized edema or erythema. There&#x000a0;are&#x000a0;no signs of coagulopathy on serial lab assessments.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Mild Envenomation: Approximately 35&#x000a0;to 40% of envenomations result in localized erythema and edema. These symptoms do not involve an entire extremity; again, there are no signs of coagulopathy on serial lab assessments.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Moderate Envenomations: Approximately 15&#x000a0;to 20% of envenomations result in more significant erythema and edema. These envenomations can affect an entire extremity. Systemic symptoms may or may not be present. Minor lab abnormalities may exist, but clinically significant bleeding does not occur.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Severe Envenomations: 5 to 10% of envenomations result in life-threatening coagulopathies with profound localized findings of erythema and edema. Severe systemic signs such as hypotension, angioedema, and any signs of neurotoxicity may present. The presence of these symptoms marks a severe envenomation regardless of other findings.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
        </list>
        <p>Patients with an apparent dry bite or mild envenomations should have monitoring for 6&#x000a0;to 8 hours. A CBC, coagulation testing, and fibrinogen should be repeated near the end of this observation period. If there are no signs of worsening envenomation, these patients can be safely discharged but should be counseled to return for any signs of bleeding, swelling, or worsening symptoms.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;All patients with more than a mild envenomation should receive antivenom.</p>
        <p>In North America, there are&#x000a0;2 Crotalidae Antivenoms approved for use:</p>
        <p>
<bold>Crotalidae Polyvalent Immune Fab Dosing</bold>
</p>
        <p>Crotalidae Polyvalent Immune Fab&#x000a0;is derived from 4 snake species&#x000a0;(western diamondback, eastern diamondback, Mojave rattlesnake, and cottonmouth) and immunized into sheep (ovine-derived). The whole immunoglobin is extracted, affinity purified, and cleaved by papain into the terminal Fab fragment of the immunoglobin. This reduces its size by about 1/3 and allows tissue penetration. However, it is cleared renally, and repeat dosing is usually necessary.</p>
        <p>The initial dose of antivenom is 4 to 6 vials, regardless of age or body mass.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref> A higher dose of 8&#x000a0;to 12 vials merits consideration for patients in shock or with serious bleeding.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref> The initial controlling dose consists of&#x000a0;4-6 vials mixed in 250 mL normal saline administered over&#x000a0;1 hour (same number of vials for children).&#x000a0;Initiate treatment&#x000a0;at 10 mL/hr, observing for adverse effects. If none, then increase every few minutes to achieve complete administration in&#x000a0;1 hour. Observe patients&#x000a0;for local swelling&#x000a0;and&#x000a0;systemic symptoms. Repeat with 4-6 vials over&#x000a0;1 hour if there are signs of progression. After completing this initial dose, a physical exam and laboratory reassessment must be performed to determine if it achieved initial control.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;A repeat dose of 4 to 6 vials is indicated if the exam and labs worsen.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;This cycle gets repeated until obtaining control. Once initial control has been obtained, patients require maintenance dosing of 2 vials at 6, 12, and 18 hours from initial control.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref> If at any point, the envenomation appears to be worsening, the algorithm should be started over with 4&#x000a0;to 6 more vials.<xref ref-type="bibr" rid="article-75841.r10">[10]</xref>&#x000a0;All patients requiring antivenom administration should be admitted for continued treatment and monitoring.</p>
        <p>Repeat coagulation panel (PT/PTT/INR), fibrinogen, platelets, and hemoglobin on days 2-3 and 5-7. Recurrent coagulopathy&#x000a0;without clinically significant bleeding&#x000a0;has been known to occur. Some repeat and follow parameters to normalization. Indications for repeat dosing if coagulopathy occurs between 3 and 7 days after the last dose of Crofab are:</p>
        <list list-type="bullet">
          <list-item>
            <p>INR &#x0003e; 3.0</p>
          </list-item>
          <list-item>
            <p>PTT &#x0003e; 50 seconds</p>
          </list-item>
          <list-item>
            <p>Platelet Count &#x0003c; 25,000</p>
          </list-item>
          <list-item>
            <p>Fibrinogen &#x0003c; 50 <italic toggle="yes">u</italic>g/ml</p>
          </list-item>
          <list-item>
            <p>Multi-component coagulopathy</p>
          </list-item>
        </list>
        <p>
<bold>Crotalidae Immune F(ab)2 Dosing</bold>
</p>
        <p>Crotalidae Immune F(ab)2 is derived from 2 snake species (<italic toggle="yes">Bothris asper</italic> and <italic toggle="yes">Crotalus duressis</italic>) and immunized in horses (equine-derived).&#x000a0; The whole immunoglobin is extracted, purified, and cleaved by pepsin digestion into a fragment with 2 binding sites for venom components - F(ab)2.&#x000a0; Though derived from horses, it is less immunogenic than the original rattlesnake antivenom. It is larger than&#x000a0;Crotalidae Polyvalent Immune Fab and persists in the serum longer with a more sustained duration of the activity; therefore, it usually does not require repeat maintenance dosing.</p>
        <p>The initial controlling dose consists of 10 vials mixed in 250 mL of normal saline and administered over&#x000a0;1 hour (the same number of vials for children). The initial infusion rate for the first 10 minutes should start at 25 to 50 ml/hr, then if no adverse reaction occurs the remaining 250 ml solution can be given over 1 hour.<xref ref-type="bibr" rid="article-75841.r12">[12]</xref>&#x000a0;It is best to evaluate the number of antivenoms available and not mix loading and maintenance doses between the&#x000a0;2 products. In rare severe envenomations, a repeat dose of 10 vials of Anavip may be needed. Blood products only temporarily correct coagulopathies and thrombocytopenia related to snake envenomation, but this rarely results in long-term correction. With this knowledge, blood products such as fresh frozen plasma, platelets, or packed red blood cells should be reserved for patients with medically significant bleeding or with profound coagulopathies despite appropriate antivenom administration.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
        <p>Aggressive surgical intervention is not indicated, including prophylactic wound excision or fasciotomy. These interventions have not been shown to change outcomes when compared to the administration of antivenom alone and can potentially&#x000a0;cause further tissue damage and be disfiguring.<xref ref-type="bibr" rid="article-75841.r13">[13]</xref>&#x000a0;Compartment syndrome is a rare but serious complication of pit viper envenomation. Diagnosing compartment syndrome should not rely on &#x0201c;soft&#x0201d; signs but should be through direct compartment pressures or evidence of neurovascular compromise where direct pressures are unobtainable.<xref ref-type="bibr" rid="article-75841.r13">[13]</xref>&#x000a0;If compartment syndrome is suspected, administer antivenom as first-line therapy before any fasciotomy or digital dermatome. Antivenom has been shown to reduce compartment pressures significantly.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref><xref ref-type="bibr" rid="article-75841.r13">[13]</xref>&#x000a0;Several therapies should be avoided as they have not been shown to change outcomes and can potentially cause more harm.</p>
        <list list-type="bullet">
          <list-item>
            <p>Excision &#x00026; Suction: Remains common practice among the lay public. Patients and healthcare providers understand that this does not remove significant venom and increases local tissue damage.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Ice: Commonly used to control localized swelling due to musculoskeletal injury, ice is ineffective at controlling swelling due to envenomation. Furthermore, intensive cryotherapy has been shown to worsen outcomes.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>NSAIDs: These agents are usually effective at pain control and&#x000a0;edema reduction. However, they theoretically potentiate the effects of venom on platelet aggregation and thus worsen bleeding. Alternative analgesics, such as opiates, should be given instead.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Electricity: Electricity plays no role in the treatment of envenomations. It increases local tissue damage and does not denature venom.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Prophylactic antibiotics: Infection appears to be a rare complication of snakebites. As such, prophylactic antibiotics are not indicated and have not been shown to change outcomes.<xref ref-type="bibr" rid="article-75841.r14">[14]</xref> &#x000a0;Antibiotics should be used only if signs of secondary infection develop, such as purulence.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Tourniquets: Tourniquets are a commonly deployed strategy despite evidence that they do not inhibit the absorption of venom effectively and can increase tissue damage. If present on the initial evaluation, any tourniquet should be removed.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Steroids: There is no evidence of improved outcomes when patients empirically receive steroids. They should be reserved only for hypersensitivity reactions to either venom or antivenom.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-75841.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>It is unlikely that a crotalid envenomation&#x000a0;is mistaken for another disease process, given that most patients present complaining of a snakebite. However, patients occasionally report concerns about a snakebite even though they cannot articulate the reason for this suspicion clearly. The primary decision point when evaluating envenomations is determining the degree of envenomation, which guides further treatment. Non-venomous snakes can also cause snakebites; however, these bites don't show any signs of toxicity, given the lack of venom. Localized reactions from other envenomations, such as Hymenoptera, can cause significant localized pain, erythema, and edema. These could be interpreted as a snake envenomation if a patient did not&#x000a0;visualize&#x000a0;the cause of their injury. However, unlike snakebites,&#x000a0;1 would expect only to see a single puncture wound instead of&#x000a0;2 and generally have limited localized edema and erythema.</p>
        <p>Patients with skin and soft tissue infections may present with concern for a snakebite. Erythema and edema from secondary infection after an injury may be mistaken for an envenomation. The development of symptoms many hours or several days after an injury is much more suggestive of secondary infection. Though not impossible, it is unlikely that a patient would suffer a snakebite without actually visualizing&#x000a0;a snake.</p>
      </sec>
      <sec id="article-75841.s10" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>Modern crotalid antivenom Fab, approved by the FDA in 2000,&#x000a0;was developed from the serum of sheep inoculated with&#x000a0;4 species native to the United States: eastern diamondback (<italic toggle="yes">C. adamanteus</italic>), western diamondback (<italic toggle="yes">C. atrox</italic>), Mojave rattlesnake (<italic toggle="yes">C. scutulatus</italic>), cottonmouth (<italic toggle="yes">A. piscivorus</italic>).<xref ref-type="bibr" rid="article-75841.r15">[15]</xref> The isolated antibodies then undergo proteolytic cleavage into the Fc and Fab portions. The Fab portion, which is less immunogenic, is then isolated and processed into the final product.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref>This modern preparation is responsible for the decreased incidence of immune reactions compared to the older preparation.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Hypersensitivity: Type I hypersensitivity is relatively uncommon, with&#x000a0;1 review&#x000a0;showing an incidence of 8%.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref> While rash was the most commonly reported symptom, there are also reports of other symptoms such as urticaria, wheezing, oral swelling, and dyspnea.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Serum Sickness: Serum sickness has also been reported, with a slightly higher incidence of 13%.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref>&#x000a0;Rash/urticaria&#x000a0;is, again, the most commonly reported symptom. Other symptoms such as myalgias, arthralgias, fever, and anorexia may be present.<xref ref-type="bibr" rid="article-75841.r15">[15]</xref>)</p>
          </list-item>
          <list-item>
            <p>Pre-treatment does not decrease the incidence of hypersensitivity reactions.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;As indicated, reactions are treated like other hypersensitivity reactions, ie, epinephrine, steroids, antihistamines, and airway management.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref> Once reaction symptoms are under control, antivenom therapy should restart slowly.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref>&#x000a0;Most patients can&#x000a0;complete their antivenom without further incident.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-75841.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>
<bold>Death</bold>
</p>
        <p>Rattlesnake envenomations resulted in 0 to 4 deaths from 1000&#x000a0;to 1300 exposures per year between 2000&#x000a0;to 2007.<xref ref-type="bibr" rid="article-75841.r13">[13]</xref>&#x000a0;Deaths from copperheads are even more rare, with&#x000a0;1 study showing only 1 death in 5 years.<xref ref-type="bibr" rid="article-75841.r13">[13]</xref>&#x000a0;Based on the available evidence, most patients receiving prompt evaluation and treatment are expected to survive.</p>
        <p>
<bold>Prolonged Disability</bold>
</p>
        <p>Patients suffering pit viper envenomation can have symptoms that persist for multiple weeks after their initial treatment. Symptom duration varies by patient and by the severity of envenomation. Generally, patients can expect symptoms to last for at least 2 to 3 weeks. Pain, decreased function of an affected extremity, persistent edema, and lost time from work can last 2 to 4 weeks. Recurrent edema and pain may occur for 1 to 2 months after envenomation.<xref ref-type="bibr" rid="article-75841.r16">[16]</xref></p>
        <p>
<bold>Recurrent Symptoms</bold>
</p>
        <p>Up to 5% of patients evaluated and treated for envenomations are readmitted after discharge. Patients are typically readmitted due to worsening symptoms, including edema/erythema or signs of coagulopathy. Recurrent coagulopathy with bleeding affects less than 1% of victims. Even fewer victims, about 0.5%, develop medically significant late bleeding.<xref ref-type="bibr" rid="article-75841.r5">[5]</xref> These patients are much more likely to have been the victims of rattlesnake envenomation.</p>
      </sec>
      <sec id="article-75841.s12" sec-type="Complications">
        <title>Complications</title>
        <p><bold>Myonecrosis/Rhabdomyolysis:</bold> Rhabdomyolysis may develop as a result of venom-induced myonecrosis. A patient&#x02019;s total&#x000a0;creatine kinase and renal function require monitoring if rhabdomyolysis is suspected. Treatment does not differ from other causes of rhabdomyolysis.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
        <p><bold>Compartment syndrome:</bold> As addressed in the previous sections, compartment syndrome is a rare but serious complication of pit viper envenomation. Any patients with suspected compartment syndrome should receive antivenom before any surgical fasciotomy or digital dermatomy. Serial compartment pressures can be obtained to monitor progression or improvement.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref><xref ref-type="bibr" rid="article-75841.r13">[13]</xref></p>
        <p><bold>Bleeding:</bold> Though clinically significant bleeding is rare, bleeding may occur either at the envenomation site or at distal sites due to the venom&#x02019;s effect on both the coagulation pathways and platelet aggregation.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref> Signs of distal bleeding commonly include gingival bleeding, epistaxis, and petechiae. However, bleeding can also present as headache or abdominal pain in the rare instance of intracranial or intraabdominal/retroperitoneal bleeding, respectively.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r3">[3]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
        <p><bold>Anemia/Thrombocytopenia:</bold> Antivenom is the first-line treatment for any hematologic abnormalities. Transfusion should only be a consideration after administering antivenom.</p>
        <p><bold>Angioedema/hives:</bold> As discussed in the previous sections, hypersensitivity reactions are uncommon. If present, treatment includes steroids, epinephrine, and antihistamines&#x000a0;in addition to antivenom. Airway management may be necessary if significant angioedema is present.<xref ref-type="bibr" rid="article-75841.r1">[1]</xref><xref ref-type="bibr" rid="article-75841.r10">[10]</xref></p>
      </sec>
      <sec id="article-75841.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Considerations for deterrence and patient education include the following:</p>
        <list list-type="order">
          <list-item>
            <p>Do not actively engage pit vipers. Many cases are preventable if people give pit vipers space to escape and do not handle them.</p>
          </list-item>
          <list-item>
            <p>Maintain situational awareness in settings where pit vipers live and hunt. Pit vipers can be encountered in many parts of the US. However, they are less common in densely populated areas. If planning a trip into sparsely populated areas, reviewing the local dangerous flora and fauna is prudent.</p>
          </list-item>
          <list-item>
            <p>Medical attention should be sought immediately for snakebites as their evaluation is inadequate outside of a medical setting. Lack of immediate symptoms does not guarantee a dry bite, and serious sequelae may take several hours to develop.</p>
          </list-item>
          <list-item>
            <p>As stated before, no attempt should be made to kill or capture the snake. A picture is usually sufficient for identification if it can be safely managed.</p>
          </list-item>
          <list-item>
            <p>Many contraindicated treatments persist as common practice among the lay public despite convincing evidence that they, at best, do not work and are more likely to cause additional harm. Patients should be counseled not to perform contraindicated treatments such as cutting, suction, electricity, ice, or tourniquets.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-75841.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>At a minimum, evaluating and managing patients with a potential crotalid envenomation requires an interprofessional team of an emergency physician, nurses, and a regional poison center. Depending on the severity of envenomation, this team may also include a hospitalist, intensivist, surgeon, and other medical or surgical subspecialties, depending on the complications of each case. Nursing staff plays a vital role in communicating changes in patient status with the treating physician. Patients suffering from envenomation require frequent reassessments and vital sign checks to monitor for disease progression. A pharmacist with board certification in applied toxicology can provide direction on antivenom dosing, preparation, and administration. They&#x000a0;are also the first to note any potential side effects from antivenom administration. Prompt communication with the regional poison control center, especially for patients with signs of significant envenomation, is crucial for&#x000a0;optimal management. Proper communication between all members of the interprofessional treatment team is vital to ensure patients receive the best evidence-based management and obtain the best outcome possible.</p>
      </sec>
      <sec id="article-75841.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=75841&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=75841">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/crotalidae-envenomation-pit-viper-bite/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=75841">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/75841/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=75841">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-75841.s16">
        <title>References</title>
        <ref id="article-75841.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kanaan</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Fuller</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Caravati</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cardwell</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Norris</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Wilderness Medical Society Practice Guidelines for the Treatment of Pitviper Envenomations in the United States and Canada.</article-title>
            <source>Wilderness Environ Med</source>
            <year>2015</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>472</fpage>
            <page-range>472-87</page-range>
            <pub-id pub-id-type="pmid">26433731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCleary</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kini</surname>
                <given-names>RM</given-names>
              </name>
            </person-group>
            <article-title>Snake bites and hemostasis/thrombosis.</article-title>
            <source>Thromb Res</source>
            <year>2013</year>
            <volume>132</volume>
            <issue>6</issue>
            <fpage>642</fpage>
            <page-range>642-6</page-range>
            <pub-id pub-id-type="pmid">24125598</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanhajariya</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Duffull</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics of Snake Venom.</article-title>
            <source>Toxins (Basel)</source>
            <year>2018</year>
            <month>Feb</month>
            <day>07</day>
            <volume>10</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">29414889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seifert</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Boyer</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Rogers</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>AAPCC database characterization of native U.S. venomous snake exposures, 2001-2005.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Apr</month>
            <volume>47</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-35</page-range>
            <pub-id pub-id-type="pmid">19514880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Daugherty</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bucher-Bartelson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>King</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Medically significant late bleeding after treated crotaline envenomation: a systematic review.</article-title>
            <source>Ann Emerg Med</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>63</volume>
            <issue>1</issue>
            <fpage>71</fpage>
            <page-range>71-78.e1</page-range>
            <pub-id pub-id-type="pmid">23567063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Walter</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Stolz</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Shirazi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McNally</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology of severe and fatal rattlesnake bites published in the American Association of Poison Control Centers' Annual Reports.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Aug</month>
            <volume>47</volume>
            <issue>7</issue>
            <fpage>663</fpage>
            <page-range>663-9</page-range>
            <pub-id pub-id-type="pmid">19640239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Neil</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Mack</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Gilchrist</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wozniak</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Snakebite injuries treated in United States emergency departments, 2001-2004.</article-title>
            <source>Wilderness Environ Med</source>
            <year>2007</year>
            <season>Winter</season>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>281</fpage>
            <page-range>281-7</page-range>
            <pub-id pub-id-type="pmid">18076294</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ruha</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kleinschmidt</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Spyres</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Brent</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wax</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Padilla-Jones</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Campleman</surname>
                <given-names>S</given-names>
              </name>
              <collab>ToxIC Snakebite Study Group</collab>
            </person-group>
            <article-title>The Epidemiology, Clinical Course, and Management of Snakebites in the North American Snakebite Registry.</article-title>
            <source>J Med Toxicol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>309</fpage>
            <page-range>309-320</page-range>
            <pub-id pub-id-type="pmid">28975491</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gerardo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Vissoci</surname>
                <given-names>JRN</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Simel</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Does This Patient Have a Severe Snake Envenomation?: The Rational Clinical Examination Systematic Review.</article-title>
            <source>JAMA Surg</source>
            <year>2019</year>
            <month>Apr</month>
            <day>01</day>
            <volume>154</volume>
            <issue>4</issue>
            <fpage>346</fpage>
            <page-range>346-354</page-range>
            <pub-id pub-id-type="pmid">30758508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Ruha</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Bebarta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Bush</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kerns</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Tanen</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Curry</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
              <collab>Rocky Mountain Poison and Drug Center, Denver Health and Hospital Authority</collab>
            </person-group>
            <article-title>Unified treatment algorithm for the management of crotaline snakebite in the United States: results of an evidence-informed consensus workshop.</article-title>
            <source>BMC Emerg Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>03</day>
            <volume>11</volume>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">21291549</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Emswiler</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Griffith</surname>
                <given-names>FP</given-names>
              </name>
              <name>
                <surname>Cumpston</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Clinically Significant Envenomation From Postmortem Copperhead (Agkistrodon contortrix).</article-title>
            <source>Wilderness Environ Med</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-45</page-range>
            <pub-id pub-id-type="pmid">27876196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mascarenas</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Fullerton</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Smolinske</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Warrick</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Comparison of F(ab')<sub>2</sub> and Fab antivenoms in rattlesnake envenomation: First year's post-marketing experience with F(ab')<sub>2</sub> in New Mexico.</article-title>
            <source>Toxicon</source>
            <year>2020</year>
            <month>Oct</month>
            <day>30</day>
            <volume>186</volume>
            <fpage>42</fpage>
            <page-range>42-45</page-range>
            <pub-id pub-id-type="pmid">32763251</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Toschlog</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Bauer</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Dart</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Surgical considerations in the management of pit viper snake envenomation.</article-title>
            <source>J Am Coll Surg</source>
            <year>2013</year>
            <month>Oct</month>
            <volume>217</volume>
            <issue>4</issue>
            <fpage>726</fpage>
            <page-range>726-35</page-range>
            <pub-id pub-id-type="pmid">23891068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>LoVecchio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Klemens</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Welch</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Antibiotics after rattlesnake envenomation.</article-title>
            <source>J Emerg Med</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>327</fpage>
            <page-range>327-8</page-range>
            <pub-id pub-id-type="pmid">12480007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schaeffer</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Khatri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Reifler</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Lavonas</surname>
                <given-names>EJ</given-names>
              </name>
            </person-group>
            <article-title>Incidence of immediate hypersensitivity reaction and serum sickness following administration of Crotalidae polyvalent immune Fab antivenom: a meta-analysis.</article-title>
            <source>Acad Emerg Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>19</volume>
            <issue>2</issue>
            <fpage>121</fpage>
            <page-range>121-31</page-range>
            <pub-id pub-id-type="pmid">22320362</pub-id>
          </element-citation>
        </ref>
        <ref id="article-75841.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spiller</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Bosse</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Prospective study of morbidity associated with snakebite envenomation.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2003</year>
            <volume>41</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-30</page-range>
            <pub-id pub-id-type="pmid">12733849</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
